Skip to main content

iRhythm Technologies Inc

For the period ended Sep 30, 2024. Filed Oct 30, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Oct 30, 2024

IRTC$86.06-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

Nine Months Ended September 30,
20242023
(unaudited)
Cash flows from operating activities
Net loss$(111,956)$(84,707)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization15,42611,434
Stock-based compensation59,97053,358
Amortization of premium and accretion of discounts, net(1,236)(3,627)
Amortization of operating lease right-of-use assets3,7474,243
Amortization of debt discount2,17312
Change in fair value of strategic investments(1,059)—
Provision for credit losses and contractual allowances52,73751,655
Acquired in-process research and development32,069—
Loss on extinguishment of debt7,589—
Impairment charges641—
Other217(378)
Changes in operating assets and liabilities:
Accounts receivable(68,680)(51,804)
Inventory(1,041)1,885
Prepaid expenses and other current assets8,165(1,549)
Other assets(614)(21,796)
Accounts payable and accrued liabilities(8,379)10,605
Deferred revenue(275)332
Operating lease liabilities(5,336)(3,792)
Net cash used in operating activities(15,842)(34,129)
Cash flows from investing activities
Purchases of property and equipment(27,098)(26,907)
Purchases of marketable securities(2,426)(109,202)
Maturities of marketable securities98,700136,500
Purchases of strategic investments(55,000)(3,000)
Purchases of acquired in-process research and development(15,000)—
Net cash used in investing activities(824)(2,609)
Cash flows from financing activities
Payment of SVB term loan and termination costs(37,751)—
Proceeds from Braidwell debt75,000—
Payments of issuance costs for Braidwell debt(2,100)—
Payment of Braidwell debt and termination costs(78,660)—
Proceeds from issuance of 2029 Notes661,250—
Payments of issuance costs for 2029 Notes(17,424)—
Purchases of capped call transactions(72,407)—
Purchase of treasury stock(25,000)—
Proceeds from issuance of common stock in connection with employee equity incentive plans5,4865,352
Net cash provided by financing activities508,3945,352
Effect of exchange rate changes on cash(8)32
Net increase (decrease) in cash, cash equivalents, and restricted cash491,720(31,354)
Cash, cash equivalents, and restricted cash, beginning of period36,17378,832
Cash, cash equivalents, and restricted cash, end of period$527,893$47,478

Condensed Consolidated Statements of Cash Flows (Continued)

Nine Months Ended September 30,
20242023
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents$519,535$47,478
Restricted cash, long-term8,358—
Total cash, cash equivalents and restricted cash$527,893$47,478
Supplemental disclosures of cash flow information:
Interest paid$6,389$2,186
Cash taxes paid$602$794
Cash received from tenant improvement allowances$736$1,603
Non-cash investing and financing activities:
Property and equipment costs included in accounts payable and accrued liabilities$173$89
Right-of-use assets obtained in exchange for operating lease liabilities$—$4,520
Capitalized stock-based compensation in property and equipment$5,530$5,596
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.